162 related articles for article (PubMed ID: 2521842)
1. Sequential therapy with recombinant interferons gamma and alpha in patients with unfavorable prognosis of chronic myelocytic leukemia: clinical responsiveness to recombinant IFN-alpha correlates with the degree of receptor down-regulation.
Bartsch HH; Pfizenmaier K; Hanusch A; Scheurich P; Ucer U; Nagel GA
Int J Cancer; 1989 Feb; 43(2):235-40. PubMed ID: 2521842
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies.
Niederle N; Kloke O; Wandl UB; Becher R; Moritz T; Opalka B
Leuk Lymphoma; 1993 Jan; 9(1-2):111-9. PubMed ID: 8477190
[TBL] [Abstract][Full Text] [Related]
3. Interferon alfa-2c in chronic myelogenous leukemia (CML): hematologic, cytogenetic and molecular-genetic response of patients with chronic phase CML previously resistant to therapy with interferon gamma.
Herrmann F; Jonas D; Helfrich SG; Lindemann A; Schleiermacher E; Mertelsmann R
Blut; 1990 Oct; 61(4):226-31. PubMed ID: 2121299
[TBL] [Abstract][Full Text] [Related]
4. Sequential treatment of Ph-positive chronic myeloid leukemia with interferon gamma and interferon alpha.
Russo D; Fanin R; Zuffa E; Damiani D; Gallizia C; Michieli M; Testoni N; Benfenati D; Visani G; Zaccaria A
Haematologica; 1990; 75(4):334-9. PubMed ID: 2125966
[TBL] [Abstract][Full Text] [Related]
5. Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous leukemia.
Claxton D; Deisseroth A; Talpaz M; Reading C; Kantarjian H; Trujillo J; Stass S; Gooch G; Spitzer G
Blood; 1992 Feb; 79(4):997-1002. PubMed ID: 1371081
[TBL] [Abstract][Full Text] [Related]
6. [Effects of recombinant human alpha-2b and gamma interferons on bone marrow megakaryocyte progenitors (CFU-Meg) from patients with chronic myelocytic leukemia].
Tanabe Y; Dan K; Kuriya S; Nomura T
Rinsho Ketsueki; 1989 Oct; 30(10):1800-5. PubMed ID: 2512397
[TBL] [Abstract][Full Text] [Related]
7. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older.
Cortes J; Kantarjian H; O'Brien S; Robertson LE; Pierce S; Talpaz M
Am J Med; 1996 Apr; 100(4):452-5. PubMed ID: 8610733
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of peripheral blood cell interferon receptors in chronic myelogenous leukemia patients undergoing human interferon (HuIFN alpha) therapy.
Maxwell BL; Talpaz M; Gutterman JU
Int J Cancer; 1985 Jul; 36(1):23-8. PubMed ID: 3160669
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Ph+ chronic myeloid leukemia by gamma interferon.
Russo D; Fanin R; Zuffa E; Gallizia C; Grazia Michieli M; Damiani D; Testoni N; Pecile V; Visani G; Colombini R
Blut; 1989 Jul; 59(1):15-20. PubMed ID: 2502210
[TBL] [Abstract][Full Text] [Related]
10. Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration.
Alimena G; Morra E; Lazzarino M; Liberati AM; Montefusco E; Inverardi D; Bernasconi P; Mancini M; Donti E; Grignani F
Blood; 1988 Aug; 72(2):642-7. PubMed ID: 3165298
[TBL] [Abstract][Full Text] [Related]
11. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha.
Wussow PV; Jakschies D; Freund M; Hehlmann R; Brockhaus F; Hochkeppel H; Horisberger M; Deicher H
Br J Haematol; 1991 Jun; 78(2):210-6. PubMed ID: 2064959
[TBL] [Abstract][Full Text] [Related]
12. Therapy of chronic myelogenous leukemia with recombinant interferon-gamma.
Kurzrock R; Talpaz M; Kantarjian H; Walters R; Saks S; Trujillo JM; Gutterman JU
Blood; 1987 Oct; 70(4):943-7. PubMed ID: 3115339
[TBL] [Abstract][Full Text] [Related]
13. Recombinant alpha-interferon as treatment for chronic myelogenous leukemia in relapse after allogeneic bone marrow transplantation: a report from the Société Française de Greffe de Moelle.
Pigneux A; Devergie A; Pochitaloff M; Rio B; Archimbaud E; Cahn JY; Leblond V; Michallet M; Jouet JP; Guilhot F
Bone Marrow Transplant; 1995 Jun; 15(6):819-24. PubMed ID: 7581075
[TBL] [Abstract][Full Text] [Related]
14. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
Lion T; Gaiger A; Henn T; Hörth E; Haas OA; Geissler K; Gadner H
Leukemia; 1995 Aug; 9(8):1353-60. PubMed ID: 7643624
[TBL] [Abstract][Full Text] [Related]
15. Interferon-alpha plus low-dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patients.
Ferrajoli A; Liberati AM; Caricchi P; Donti E; Morra E; Lazzarino M; Betti AR; Bernasconi P; Saglio G
Eur J Haematol; 1995 Sep; 55(3):184-8. PubMed ID: 7672091
[TBL] [Abstract][Full Text] [Related]
16. A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemia.
Kloke O; Wandl U; Opalka B; Moritz T; Nagel-Hiemke M; Franz T; Becher R; Hirche H; Seeber S; Niederle N
Eur J Haematol; 1992 Feb; 48(2):93-8. PubMed ID: 1547881
[TBL] [Abstract][Full Text] [Related]
17. Alpha interferon: perspectives in the biotherapy of chronic myelogenous leukemia.
Terebelo HR
Oncol Nurs Forum; 1991; 18(1 Suppl):5-9. PubMed ID: 1997975
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic myelogenous leukemia with interferons alpha and gamma.
Kloke O; May D; Wandl U; Becher R; Opalka B; Beer U; Niederle N
Blut; 1990 Jul; 61(1):45-6. PubMed ID: 2117476
[TBL] [Abstract][Full Text] [Related]
19. Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study. Austrian Biological Response Modifier (BRM) Study Group.
Thaler J; Gastl G; Fluckinger T; Niederwieser D; Huber H; Seewann H; Sill H; Lang A; Falk M; Duba C; Utermann G; Kühr T; Aulitzky W; Huber C
Ann Hematol; 1996 Jun; 72(6):349-55. PubMed ID: 8767103
[TBL] [Abstract][Full Text] [Related]
20. Clonogenic assay is not predictive but reflects therapeutic efficacy of interferons in the treatment of chronic myelogenous leukemia.
Wandl UB; Niederle N; Kranzhoff M; Seeber S
Int J Cell Cloning; 1992 Sep; 10(5):292-8. PubMed ID: 1453016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
